Publications by authors named "S Stemmer"
Article Synopsis
- - The RSClinN+ tool was developed to better predict recurrence risk and the benefits of chemotherapy specifically for patients with HR+/HER2-negative, lymph node-positive breast cancer, by incorporating both the Oncotype DX score and other clinical factors like tumor size and age.
- - Analysis of data from over 5,000 patients revealed that RSClinN+ offered significantly improved prognostic accuracy compared to using the Oncotype DX score alone or clinicopathological models, especially for premenopausal and postmenopausal women.
- - Validation of RSClinN+ showed that it effectively estimates prognosis and potential chemotherapy benefits, making it a valuable personalized tool for clinicians in managing breast cancer treatment decisions.
Purpose: To evaluate the association between the HER2 score as provided by the Oncotype DX Recurrence Score (RS) assay, tumor characteristics, and outcomes in early-stage, ER + HER2-negative breast cancer (BC).
Methods: All women insured by the Clalit Health Services, with early-stage, ER + HER2-negative BC who underwent RS testing between 2008 and 2011 were included. Patient/tumor characteristics and Kaplan-Meier estimates for distant recurrence-free survival (DRFS) and overall survival (OS) were compared by HER2 category, based on the HER2 score provided by the RS assay: lower HER2 score group representing the lower third of the HER2 score range (≤ 8.
Background: Atypical and anaplastic meningiomas account for 20% of all meningioma cases. Solitary fibrous tumor (SFT) is a type of soft tissue sarcoma with similar attributes to meningioma. For patients with refractory or recurrent disease after previous surgery or radiotherapy, there is no effective treatment.
View Article and Find Full Text PDFDirac and Weyl semimetals, such as cadmium arsenide (CdAs), have recently attracted attention for use in high-speed photodetectors that operate at longer infrared wavelengths, where conventional semiconductor-based photodetectors have a limited performance. In this Letter, we explore near-infrared (960 nm) photodetection in a CdAs/AlSb heterojunction. We show that CdAs/AlSb heterojunctions allow for an unbiased operation and demonstrate an enhanced responsivity and quantum efficiency compared to AlSb and CdAs reference devices.
View Article and Find Full Text PDFArticle Synopsis
- The 21-gene recurrence score (RS) test, called Oncotype DX, helps decide if breast cancer patients need chemotherapy.
- Researchers studied over 10,000 women to see how well the RS works with other information like tumor size and patient age to predict cancer recurrence after treatment.
- They found that combining the RS with other factors gives much better predictions about whether the cancer will come back, especially between 5 to 10 years after diagnosis.